A polymyxin-based potentiator for treatment of MDR Gram-negative bacterial infections

奥尼尔的报告将抗生素耐药性确定为威胁我们生活方式的最重要问题之一。据估计，如果不解决这一威胁，到2050年，每年将有1 000万人死亡，经济损失将达100万亿美元。该项目解决了最难治疗的细菌病原体类别之一，该细菌病原体正变得几乎所有可用的治疗选择- MDR革兰氏阴性菌。对于这些细菌，一类称为碳青霉烯类的抗生素是治疗的主要药物，直到对该类抗生素的耐药性开始发展。一种叫做多粘菌素的古老抗生素类，虽然毒性很大，但后来又被恢复，以提供一个有点不完美的停止缺口。在治疗病毒性疾病甚至细菌感染如结核病时，公认的是需要药物的组合来进行有效治疗。Cantab计划开发一种新型低毒性多粘菌素衍生物与合作抗生素的创新组合，即使是最难治疗的感染也能有效治疗。需要公众的支持来解决抗菌市场的经济不确定性，并帮助确保Cantab作为英国抗生素开发商的未来。

The O'Neill report identifies antibiotic resistance as one of the most important issues threatening our way of life. The potential consequences of failure to address this threat are assessed as 10 million deaths per annum by 2050 at an economic cost of 100 trillion US dollars. This project addresses one of the most difficult to treat classes of bacterial pathogen which is becoming recalcitrant to almost all available therapeutic options - MDR Gram-negative bacteria. For these bacteria, a class of antibiotics called carbapenems was the mainstay of treatment until resistance to this class started to develop. An old antibiotic class called polymyxins, whilst rather toxic, was then revived to provide a somewhat imperfect stop gap. In treatment of viral diseases and even bacterial infections such as tuberculosis, it is accepted that combinations of drugs are needed for effective treatment. Cantab is proposing to develop an innovative combination of a novel low toxicity polymyxin derivative with a partner antibiotic which is able to provide effective coverage for even the most difficult to treat infections. Public support is needed to address the economic uncertainties of the antibacterial market and to help to secure the future of Cantab as a UK-based antibiotic developer.